Market Overview

UPDATE: Credit Suisse Initiates Sequenom at Underperform on Competitive Challenges

Related SQNM
Sequenom Labs Reports Expanded Int'l Noninvasive Prenatal Testing Service with VisibiliT Test
UPDATE: Jefferies Resumes Coverage On Sequenom On Revised Revenue/EPS Forecasts

Credit Suisse initiated coverage on Sequenom (NASDAQ: SQNM) with an Underperform rating and a $4 price target.

Credit Suisse noted, "While we are excited about the scientific advance and volume potential that noninvasive prenatal genetic tests, including Sequenom's MaterniT21 PLUS, offer, we are concerned that the aggressive competitive dynamics we are already seeing (most notably with pricing) will limit the commercial potential of the test and cause the stock to underperform the rest of our coverage universe over the next 12 months."

Sequenom closed at $3.70 on Monday.

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (SQNM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters